Yvette M Carter1, Selvi Kunnimalaiyaan2, Herbert Chen1, T Clark Gamblin3, Muthusamy Kunnimalaiyaan2. 1. University of Wisconsin Endocrine Surgery Laboratory; Madison, WI USA. 2. University of Wisconsin Endocrine Surgery Laboratory; Madison, WI USA; Medical College of Wisconsin; Milwaukee, WI USA. 3. Medical College of Wisconsin; Milwaukee, WI USA.
Abstract
OBJECTIVE: Neuroblastoma is a common neuroendocrine (NE) tumor that presents in early childhood, with a high incidence of malignancy and recurrence. The glycogen synthase kinase-3 (GSK-3) pathway is a potential therapeutic target, as this pathway has been shown to be crucial in the management of other NE tumors. However, it is not known which isoform is necessary for growth inhibition. In this study, we investigated the effect of the GSK-3 inhibitor AR-A014418 on the different GSK-3 isoforms in neuroblastoma. METHODS: NGP and SH-5Y-SY cells were treated with 0-20 μM of AR-A014418 and cell viability was measured by MTT assay. Expression levels of NE markers CgA and ASCL1, GSK-3 isoforms, and apoptotic markers were analyzed by western blot. RESULTS: Neuroblastoma cells treated with AR-A014418 had a significant reduction in growth at all doses and time points (P<0.001). A reduction in growth was noted in cell lines on day 6, with 10 μM (NGP-53% vs. 0% and SH-5Y-SY-38% vs. 0%, P<0.001) treatment compared to control, corresponding with a noticeable reduction in tumor marker ASCL1 and CgA expression. CONCLUSION: Treatment of neuroblastoma cell lines with AR-A014418 reduced the level of GSK-3α phosphorylation at Tyr279 compared to GSK-3β phosphorylation at Tyr216, and attenuated growth via the maintenance of apoptosis. This study supports further investigation to elucidate the mechanism(s) by which GSK-3α inhibition downregulates the expression of NE tumor markers and growth of neuroblastoma.
OBJECTIVE:Neuroblastoma is a common neuroendocrine (NE) tumor that presents in early childhood, with a high incidence of malignancy and recurrence. The glycogen synthase kinase-3 (GSK-3) pathway is a potential therapeutic target, as this pathway has been shown to be crucial in the management of other NE tumors. However, it is not known which isoform is necessary for growth inhibition. In this study, we investigated the effect of the GSK-3 inhibitor AR-A014418 on the different GSK-3 isoforms in neuroblastoma. METHODS: NGP and SH-5Y-SY cells were treated with 0-20 μM of AR-A014418 and cell viability was measured by MTT assay. Expression levels of NE markers CgA and ASCL1, GSK-3 isoforms, and apoptotic markers were analyzed by western blot. RESULTS:Neuroblastoma cells treated with AR-A014418 had a significant reduction in growth at all doses and time points (P<0.001). A reduction in growth was noted in cell lines on day 6, with 10 μM (NGP-53% vs. 0% and SH-5Y-SY-38% vs. 0%, P<0.001) treatment compared to control, corresponding with a noticeable reduction in tumor marker ASCL1 and CgA expression. CONCLUSION: Treatment of neuroblastoma cell lines with AR-A014418 reduced the level of GSK-3α phosphorylation at Tyr279 compared to GSK-3β phosphorylation at Tyr216, and attenuated growth via the maintenance of apoptosis. This study supports further investigation to elucidate the mechanism(s) by which GSK-3α inhibition downregulates the expression of NE tumor markers and growth of neuroblastoma.
Authors: Ruth Ho; Angelika Eggert; Tomoro Hishiki; Jane E Minturn; Naohiko Ikegaki; Patricia Foster; Anna Marie Camoratto; Audrey E Evans; Garrett M Brodeur Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: Andrei V Ougolkov; Martin E Fernandez-Zapico; Doris N Savoy; Raul A Urrutia; Daniel D Billadeau Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701
Authors: David Yu Greenblatt; Max A Cayo; Joel T Adler; Li Ning; Megan R Haymart; Muthusamy Kunnimalaiyaan; Herbert Chen Journal: Ann Surg Date: 2008-06 Impact factor: 12.969
Authors: Andrey V Ugolkov; Gennadiy I Bondarenko; Oleksii Dubrovskyi; Ana P Berbegall; Samuel Navarro; Rosa Noguera; Thomas V O'Halloran; Mary J Hendrix; Francis J Giles; Andrew P Mazar Journal: Anticancer Drugs Date: 2018-09 Impact factor: 2.248
Authors: Selvi Kunnimalaiyaan; Jose Trevino; Susan Tsai; T Clark Gamblin; Muthusamy Kunnimalaiyaan Journal: Mol Cancer Ther Date: 2015-04-17 Impact factor: 6.261
Authors: Amy Walz; Andrey Ugolkov; Sunandana Chandra; Alan Kozikowski; Benedito A Carneiro; Thomas V O'Halloran; Francis J Giles; Daniel D Billadeau; Andrew P Mazar Journal: Clin Cancer Res Date: 2017-01-04 Impact factor: 12.531
Authors: Andrey Ugolkov; Irina Gaisina; Jin-San Zhang; Daniel D Billadeau; Kevin White; Alan Kozikowski; Sarika Jain; Massimo Cristofanilli; Francis Giles; Thomas O'Halloran; Vincent L Cryns; Andrew P Mazar Journal: Cancer Lett Date: 2016-07-14 Impact factor: 8.679
Authors: Selvi Kunnimalaiyaan; Kevin M Sokolowski; Mariappan Balamurugan; T Clark Gamblin; Muthusamy Kunnimalaiyaan Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Jeroen Middelbeek; Daan Visser; Linda Henneman; Alwin Kamermans; Arthur J Kuipers; Peter M Hoogerbrugge; Kees Jalink; Frank N van Leeuwen Journal: Oncotarget Date: 2015-04-20